Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1642 of 6351
-
Zapping pancreatic tumors with heat: a Needle-Sized hope
Disease control Recruiting nowTranscutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment o…
Sponsor: Sahlgrenska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill takes on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThe purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Phase 1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Pregnant women with hepatitis b: which drug is safer?
Disease control By invitation onlyThe goal of this clinical trial is to study the efficacy and safety of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate(TDF) in early and middle pregnancy with chronic hepatitis B.
Phase 4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for depression in spinal cord injury: brain stimulation without hand movement
Symptom relief Recruiting nowDepression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Can a common allergy drug plus special sounds restore hearing in noise?
Symptom relief Recruiting nowThe goal of this clinical trial is to determine the efficacy of Clemastine Fumarate in the presence of engineered sound to treat age-related central auditory processing disorder (CAPD). This disorder impacts 800M patients worldwide, including \~1/3 people over 40 years of age and…
Phase 1/2 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
New shot aims to shield celiac patients from gluten damage
Disease control OngoingThe primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary obj…
Phase 2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a common antibiotic prevent STIs? new study tests two dosing strategies
Prevention OngoingThe goal of this clinical trial is to compare the effectiveness of doxycycline taken for on-demand pre-exposure prophylaxis (DoxyODPrEP) and its post-exposure use (DoxyPEP) in preventing bacterial sexually transmitted infections (STI), including chlamydia, gonorrhoea, and syphili…
Phase 4 • Sponsor: Chinese University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Can a light beam clear stubborn blackheads?
Disease control CompletedThe aim of this study is to evaluate the clinical efficacy and safety of the 577 nm diode laser in the treatment of non -inflammatory acne.
Sponsor: Al-Azhar University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for Hard-to-Treat skin cancer: PTX-100 enters phase 2 trial
Disease control Recruiting nowThis is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV …
Phase 2 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Sep 10, 2026 06:00 UTC
-
New diabetes drug aims to help when current meds fall short
Disease control Recruiting nowThe purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last abo…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug aims to boost immune system against tough cancers
Disease control OngoingThis study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug epcoritamab tested in Real-World lymphoma patients
Disease control Recruiting nowDiffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill could tame severe ulcerative colitis Flare-Ups
Disease control Recruiting nowThis is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of S…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double-Barreled CAR-T takes aim at Hard-to-Treat myeloma
Disease control Recruiting now1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma. 2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple mye…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a simple injection ease Post-Stroke shoulder pain?
Symptom relief Recruiting nowShoulder pain is extremely common after stroke and occurs in 30-70% of patients. The pain may begin as early as one week after stroke, although peak onset and severity occurs around four months, and persists into the chronic stage. Chronic post stroke shoulder pain (PSSP) interfe…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Could a common mental health drug prevent weight loss in cancer patients?
Symptom relief Recruiting nowThe goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are: Is prolonged low-dose olanzapine effective and save in: * Preventing/treating weight l…
Phase 3 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a diabetes drug boost bariatric surgery results?
Disease control Recruiting nowThis clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity. The major objectives are: 1. To evaluate whether pre-operat…
Phase 4 • Sponsor: Marlene Starr • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingGH2616 is a potent and selective inhibitor targeting KIF18A, exhibiting distinct and superior anticancer properties compared to other cell cycle and anti-mitotic drug targets, with significant inhibitory effects on TP53 mutant and WGD (whole genome doubling) or CIN (chromosomal i…
Phase 1 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Cooling gel could flip the Body's Fat-Burning switch
Knowledge-focused CompletedBrown adipose tissue becomes activated during cold conditions to increase thermogenesis (i.e., energy expenditure). Topical menthol application increases resting energy expenditure but it is unclear whether brown adipose tissue activation contributes to this rise in the energy ex…
Early phase 1 • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can faster brain zaps beat depression in seniors?
Symptom relief Recruiting nowThe purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where participants receive a single TBS treatment daily) in lat…
Sponsor: Centre for Addiction and Mental Health • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC